- Home
- AMSF vs COGT Comparison
AMSF vs COGT Comparison
Compare AMSF & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMSF
- COGT
- Stock Information
- Founded
- AMSF 1985
- COGT 2014
- Country
- AMSF United States
- COGT United States
- Employees
- AMSF N/A
- COGT N/A
- Industry
- AMSF Accident &Health Insurance
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- AMSF Finance
- COGT Health Care
- Exchange
- AMSF Nasdaq
- COGT Nasdaq
- Market Cap
- AMSF 869.6M
- COGT 817.5M
- IPO Year
- AMSF 2005
- COGT 2018
- Fundamental
- Price
- AMSF $44.16
- COGT $11.19
- Analyst Decision
- AMSF Buy
- COGT Strong Buy
- Analyst Count
- AMSF 2
- COGT 9
- Target Price
- AMSF $59.50
- COGT $19.38
- AVG Volume (30 Days)
- AMSF 140.5K
- COGT 4.7M
- Earning Date
- AMSF 07-24-2025
- COGT 08-05-2025
- Dividend Yield
- AMSF 10.35%
- COGT N/A
- EPS Growth
- AMSF N/A
- COGT N/A
- EPS
- AMSF 2.48
- COGT N/A
- Revenue
- AMSF $301,216,000.00
- COGT N/A
- Revenue This Year
- AMSF $1.69
- COGT N/A
- Revenue Next Year
- AMSF $6.54
- COGT N/A
- P/E Ratio
- AMSF $17.77
- COGT N/A
- Revenue Growth
- AMSF N/A
- COGT N/A
- 52 Week Low
- AMSF $42.48
- COGT $3.72
- 52 Week High
- AMSF $60.24
- COGT $12.61
- Technical
- Relative Strength Index (RSI)
- AMSF 47.66
- COGT 87.74
- Support Level
- AMSF $42.80
- COGT $7.07
- Resistance Level
- AMSF $44.19
- COGT $10.23
- Average True Range (ATR)
- AMSF 0.91
- COGT 0.66
- MACD
- AMSF 0.14
- COGT 0.37
- Stochastic Oscillator
- AMSF 81.55
- COGT 99.89
About AMSF AMERISAFE Inc.
AMERISAFE Inc is a specialty provider of workers' compensation insurance focused on small to mid-sized employers engaged in hazardous industries, principally construction, trucking, logging and lumber, agriculture, manufacturing, maritime, and telecommunications. The company generates a majority of its revenue in the form of premiums.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.